Agilent TechnologiesFRA:AG8 -0.25%91 EBITDA Margin % is 27.25% as of Apr. 2026, which is 9% above its 10-year median of 25.00. GuruFocus rates FRA:AG8 with a GF Score™ of 91/100 and a GF Value™ of €127.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 204 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 85.29% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Agilent Technologies EBITDA Margin % Related Terms
Agilent Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AG8 vs WAT, IDXX, NTRA: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (FRA:AG8) has a EBITDA Margin % of 27.25% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Agilent Technologies and its competitors. This is near median its historical median of 25.00. Over the past decade, Agilent Technologies' EBITDA Margin % has ranged from 20.51 to 28.79. According to the industry distribution chart, Agilent Technologies ranks #30 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 14.7%.
Is Agilent Technologies' EBITDA Margin % too high?
Agilent Technologies' current EBITDA Margin % of 27.25% is near median its 10-year median of 25.00. Over the past 10 years, this metric has ranged from a low of 20.51 to a high of 28.79. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Agilent Technologies' value of 27.25% is 424% above this industry median. Based on the distribution chart, Agilent Technologies ranks #30 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Agilent Technologies has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' EBITDA Margin % compare to WAT and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #30 out of 204 companies for EBITDA Margin %. This places Agilent Technologies in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Agilent Technologies' value of 27.25% is 424% above this benchmark. Historically, Agilent Technologies' own EBITDA Margin % has ranged from 20.51 to 28.79 over the past decade. While the company's 10-year median is 25.00 vs. the industry median of 5.20, Agilent Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agilent Technologies's current EBITDA Margin % of 27.25% is 424% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Agilent Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current EBITDA Margin % is 27.25%, which is near median its own 10-year median of 25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Fairly Valued. The stock's GF Value™ is €127.48, compared to a current price of €119.35 — trading 6.4% below its estimated fair value. The current EBITDA Margin % is 27.25%, which is near median its 10-year median of 25.00 and 424% above the Medical Diagnostics & Research industry median of 5.20. Agilent Technologies' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current EBITDA Margin % is 27.25% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (FRA:AG8) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €119.35 is trading 6.4% below its estimated GF Value™ of €127.48.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for FRA:AG8:
EBITDA Margin %: 27.25% (near median its 10-year median of 25.00)
GF Value™: €127.48 vs. price of €119.35 (6.4% below fair value)
Industry Position: 424% above the Medical Diagnostics & Research median (#30 of 204)
No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
91GF Score
Get the complete analysis for FRA:AG8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AG8 has been successfully added to your 
